CETi-1. AVANT.
CETi-1, a vaccine that stimulates antibodies specific for cholesteryl ester transfer protein, is under development by AVANT Immunotherapeutics for potential use in reducing risk factors for atherosclerosis. Phase II trials with CETi-1 in hypercholesterolemia and atherosclerosis had been initiated by August 2001.
Animals↗